Amisulpride API Powder

Amisulpride API manufactured by Swapnroop Drugs & Pharmaceuticals is a high-purity active pharmaceutical ingredient (API) used primarily in the treatment of various mental health conditions, particularly schizophrenia and acute psychotic episodes.

Key Details:

•  Therapeutic Class: Atypical antipsychotic
• Mechanism of Action: Acts as a selective dopamine D₂/D₃ receptor antagonist, helping to restore the balance of neurotransmitters in the brain.
• Form: High-quality, bulk API (Active Pharmaceutical Ingredient) suitable for formulation into tablets or injectable medications.
• Certifications:
• WHO-GMP Certified
• ISO Certified Manufacturing Facility
• Use Cases:
• Schizophrenia (positive and negative symptoms)
• Dysthymia and other depressive disorders (off-label in some regions)

Swapnroop’s API ensures consistency, regulatory compliance, and is suitable for export to regulated markets globally.

Would you like a product brochure or detailed technical specification sheet (TDS/MSDS) for this API?

What is  Amisulpride API Manufactured by Swapnroop Drugs and Pharmaceuticals used for?

Therapeutic Applications of Amisulpride API

Manufactured by Swapnroop Drugs & Pharmaceuticals (WHO-GMP & ISO 9001:2015 Certified)

Amisulpride API is a selective dopamine D2/D3 receptor antagonist classified as an atypical antipsychotic. It is primarily used to treat psychiatric disorders due to its unique limbic system specificity. Below are its key therapeutic uses, supported by clinical and regulatory data:

1. Approved Indications

A. Schizophrenia

• Target Symptoms:
• Positive Symptoms: Hallucinations, delusions, thought disorders.
• Negative Symptoms: Social withdrawal, emotional blunting, anhedonia.
• Dosage Range:
• 400–800 mg/day (split doses for doses >400 mg).
• Low doses (50–300 mg/day) preferentially improve negative symptoms.

B. Acute Psychotic Episodes

• Rapid Action: Reduces agitation and aggression within 3–7 days.
• IM Formulation: Used in hospital settings for acute control.

2. Off-Label Uses (Clinically Supported)

A. Dysthymia & Depression

• Mechanism: Dopamine modulation in mesolimbic pathways.
• Dose: 50 mg/day (significantly lower than antipsychotic doses).